Skip to main content
Premium Trial:

Request an Annual Quote

Incyte, SmithKline License Xenometrix's Patented Gene Expression Profiling

Premium

BOULDER, Colo.--Xenometrix, a biotechnology firm here announced last month that it granted licenses to both Incyte and SmithKline Beecham for its gene expression profiling technology. The nonexclusive license for the technology, for which Xenometrix received a US patent in September, covers the collection of gene expression profiles utilizing all methods, including high-density microarrays. Gene Logic, Rosetta Inpharmatics, Cerep, Affymetrix, and Aurora Biosciences are among other companies that have licensed the Xenometrix technology. SmithKline is Xenometrix's first large pharmaceutical customer.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.